Click for next page ( 112


The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 111
References Ahonkhai, V. 2012. Regulatory issues affecting MDR-TB SLDs. Presentation at IOM work- shop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. Atun, R. 2012. Challenges and barriers to efficient operation of existing supply chain. Presen- tation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. Cepheid. 2012. Cepheid announces first phase of Xpert MTB/RIF buy-down for high burden developing countries. http://www.cepheid.com/company/news-events/press- releases/?releaseID=698417 (accessed October 1, 2012). Comstock, G. 2012. Learning from other models: PEPFAR’s supply chain management system (SCMS). Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. Ditiu, L. 2012. GDF vision for SLD supply chain. Presentation at IOM workshop on Devel- oping and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug- Resistant Tuberculosis, July 31–August 1, Washington, DC. Fraser, H. S., J. Blaya, S. S. Choi, C. Bonilla, and D. Jazayeri. 2006. Evaluating the impact and costs of deploying an electronic medical record system to support TB treatment in Peru. AMIA Annual Symposium Proceedings 264-268. Hedman, L. 2012. Quality of 2nd line medicines for tuberculosis. Presentation at IOM work- shop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. IOM (Institute of Medicine). 2009. Addressing the threat of drug-resistant tuberculosis: A realistic assessment of the challenge: Workshop summary. Washington, DC: The National Academies Press. IOM. 2011a. The emerging threat of drug-resistant tuberculosis in Southern Africa: Global and local challenges and solutions: Workshop summary. Washington, DC: The National Academies Press. 111

OCR for page 111
112 GLOBAL SUPPLY CHAIN FOR SECOND-LINE DRUGS FOR MDR TB IOM. 2011b. The new profile of drug-resistant tuberculosis in Russia: A global and local perspective: Workshop summary. Washington, DC: The National Academies Press. IOM. 2012. Facing the reality of drug-resistant tuberculosis in India: Challenges and potential solutions: Workshop summary. Washington, DC: The National Academies Press. Keshavjee, S. 2012. Background on the Green Light Committee and the second line tubercu- losis drug supply chain. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. Keshavjee, S., and P. Farmer. 2012. Tuberculosis, drug resistance, and the history of modern medicine. New England Journal of Medicine 367(10):931-936. Keshavjee, S., and K. Seung. 2008. Stemming the tide of multidrug-resistant tuberculo- sis: Major barriers to addressing the growing epidemic. http://www.iom.edu/~/media/ Files/Activity%20Files/Research/DrugForum/IOM_MDRTB_whitepaper_2009_01_14_ FINAL_Edited.pdf (accessed September 15, 2011). Kimerling, M. 2012. SLD Financing Issues: IOM workshop on the global supply chain for second-line drugs for MDR-TB. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. Mostaghim, S. 2012. MDR-TB drugs: Challenges and barriers to efficient operation of exist- ing supply chain. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. MSF (Médecins Sans Frontières) and IUATLD (International Union Against Tuberculosis and Lung Disease). 2011. DR-TB drugs under the microscope: Sources and prices for drug- resistant tuberculosis medicines. http://www.msfaccess.org/our-work/addressing-medical- challenges/article/888 (accessed October 1, 2012). MSH (Management Sciences for Health). 2011. Quality assurance for pharmaceuticals. http:// www.msh.org/resource-center/publications/upload/MDS3-Ch19-QualityAssurance- Nov2011.pdf (accessed November 13, 2012). Ripin, D. 2012. Lessons learned from catalyzing and sustaining access to pediatric HIV treat- ments. Presentation at IOM workshop on Developing and Strengthening the Global Sup- ply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. Sims, T. 2012. Creating innovative solutions for MDR-TB: Ideas from the MDR-TB inno- vation summit. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. Wallengren, K., F. Scano, P. Nunn, B. Margot, S. Buthelezi, B. Williams, A. Pym, E. Y. Samuel, F. Mirzayev, W. Nkhoma, L. Mvusi, and Y. Pillay. 2011. Drug-resistant tu- berculosis, KwaZulu-Natal, South Africa, 2001-2007. Emerging Infectious Diseases 17(10):1913-1916. Walsh, J. A., and K. S. Warren. 1979. Selective primary health care: An interim strategy for dis- ease control in developing countries. New England Journal of Medicine 301(18):967-974. WHO (World Health Organization). 2006. Guidelines for the programmatic management of drug-resistant tuberculosis. http://whqlibdoc.who.int/publications/2006/9241546956_ eng.pdf (accessed October 1, 2012). WHO. 2010. Global Tuberculosis Control: WHO report 2010. http://www.who.int/tb/ publications/global_report/2010/en/index.html (accessed September 18, 2011).

OCR for page 111
REFERENCES 113 Yadav, P. 2012. Supply chain for MDR-TB: Challenges and ideas for improvement. Presenta- tion at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC. Zhao, Y., S. Xu, L. Wang, D. P. Chin, S. Wang, G. Jiang, H. Xia, Y. Zhou, Q. Li, X. Ou, Y. Pang, Y. Song, B. Zhao, H. Zhang, G. He, J. Guo, and Y. Wang. 2012. National Survey of Drug-Resistant Tuberculosis in China. New England Journal of Medicine 366(23):2161-2170.

OCR for page 111